Oxford Biomedica

Are you attending Phacilitate Advanced Therapies Europe 2024 in Lisbon next week? Don’t miss the opportunity to join Carol Knevelman, VP of Technical Excellence, on 11th September as she discusses key strategies we've implemented to advance the next generation of lentiviral vectors. Carol will showcase: 🔹 The development of a novel lentiviral vector backbone with improved characteristics 🔹Development of a new manufacturing process utilising perfusion cell culture 🔹Future innovations aimed at overcoming vector purification challenges If you would you like to set up a meeting at the conference to learn more about our viral vector capabilities, please reach out to Ahmed YAHIA or Carol Knevelman, or email [email protected]. We look forward to connecting with you at the conference! #CDMO #ViralVectors #LentiviralVectors #CellAndGeneTherapy #ATE24

Today we are delighted to announce that Lucinda Crabtree, PhD has joined OXB as CFO and board member! Lucinda (Lucy) was previously at MorphoSys AG where she served as CFO until the company’s acquisition by Novartis. Prior to that she was CFO at Autolus Therapeutics, a Nasdaq listed clinical stage biopharmaceutical company. Lucy has extensive experience in the investment and banking sectors, and we are thrilled to have her onboard as we grow our international position as a leading cell and gene therapy CDMO. Welcome Lucy! #CDMO #ViralVectors #CellAndGeneTherapy #CFO #ChiefFinancialOfficer #Recruitment #BoardOfDirectors #ExecutiveDirector

We know how important on time delivery is for our clients, which is why in the last 12 months we have delivered 100% of our AAV batches on time with >65% of these delivered ahead of schedule. #CDMO #AAV #ViralVectors #CellAndGeneTherapy #TrackRecord

Are you thinking of scaling up to 2,000L? Our 'plug and play' inAAVate™ platform has been successfully scaled from 50L to 2,000L, and delivers bioreactor vg titer up to 10-fold over current industry standard. #AAV #CDMO #ViralVectors #CellAndGeneTherapy

Join us for our upcoming free 60-minute webinar at 16:00 BST / 11:00 EDT / 17:00 CET on Wednesday 11th September 2024 to learn about our AAV development expertise and recent breakthroughs! Our speakers will delve into how the characterisation of the contents and surface of AAV capsids has helped identify factors influencing charge heterogeneity, and consequently, the potency of AAV products. To register for the webinar, please click here: https://lnkd.in/eykthwfW #AAV #Webinar #CDMO #ViralVectors #Bioprocessing

At OXB, we design optimal vectors to boost productivity and minimize the occurrence of partial capsids, resulting in a more cost-effective process and more powerful therapies. #AAV #ViralVectors #CellAndGeneTherapy #VectorEngineering

Next Thursday at 11am EDT, Dr. Serena Dollive, PhD, Senior Scientist II, will be presenting her group's work on characterizing AAV gene therapies using PacBio long-read sequencing at the 16th Annual Bioprocessing Summit in Boston. If you’d like to hear how we can quantitate residual impurities as well as vector subspecies all within one assay for deeper, more comprehensive understanding of vector batch content, be sure to listen to Serena’s talk! #Conference #Bioprocessing #CDMO #AAV #ViralVectors #CellAndGeneTherapy

As an innovation-led viral vector CDMO, we are constantly innovating to improve vector titre, quality, potency, safety and scalability, to speed up the time it takes our clients to move their programmes through clinical trials to GMP manufacturing. #CDMO #ViralVectors #Innovation #CellAndGeneTherapy #GMP

In this newly published, peer-reviewed paper, we demonstrate a 2-fold increase in AAV productivity through the use of a minimize helper plasmid containing deletions in the E2a and E4 adenovirus genes. The minimized helper plasmid generated reduced E4orf6 expression that was correlated with an increase in vector genome production. This finding highlights that native adenovirus gene expression utilized in most currently available helper plasmids does not provide the optimal conditions for AAV production and suggests that further fine-tuning helper gene expression could unlock additional titer increases. Read the paper here: https://lnkd.in/ehmZm2sQ #CDMO #ViralVectors #Innovation #CellAndGeneTherapy #AAV

This morning, we shared a trading update for the first half of 2024 showing the strong demand for CDMO services we are experiencing. We reiterate our medium-term financial guidance of a three-year revenue CAGR in excess of 35% for 2023-2026, to be profitable on an Operating EBITDA level in 2025, with Operating EBITDA margins in excess of 20% by the end of 2026. Read the press release here: https://lnkd.in/eSHRXWgZ #CDMO #ViralVectors #CellAndGeneTherapy